12 Best Multibagger Stocks to Buy Heading into 2026

6. Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Market Cap: $796.92 Million

Price Return over 1-Year: 166.08%

Upside Potential: 90.40%

Number of Hedge Fund Holders: 27

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is one of the 12 best multibagger stocks to buy heading into 2026.

Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst sentiment around Fulcrum Therapeutics, Inc. (NASDAQ:FULC) appears to be growing.

As of December 18, 2025, 80% of analysts are bullish on Fulcrum Therapeutics, Inc. (NASDAQ:FULC), setting a median price target of $18.00. This translates to a 90.40% upside potential.

One such update came from Truist on December 11, 2025, where the firm raised its price target on Fulcrum Therapeutics, Inc. (NASDAQ:FULC) from $14 to $18, while reiterating a “Buy” rating, according to The Fly. The bank attributed its bullish stance to sustained positive reception around partial Cohort 4 data. According to the firm, the readout is a clear win for the company, reflecting growing confidence in pociredir’s emerging clinical profile.

Meanwhile, on December 9, 2025, Bank of America also increased its price target on Fulcrum Therapeutics, Inc. (NASDAQ:FULC) from $6 to $7. However, the bank reiterated an “Underperform” rating. The firm expects a potential 2029 launch for pociredir in sickle cell disease, assuming nominal peak sales of $1.5 billion by 2038.

These updates were preceded by Fulcrum Therapeutics, Inc. (NASDAQ:FULC)’s December 6, 2025, press release, which detailed positive initial results from the 20 mg dose cohort of the PIONEER study. The positives highlighted by management included robust early increases in fetal hemoglobin, a clear dose-response versus lower doses, and a favorable safety profile with no serious side effects. With these positives, the company reinforced pociredir’s potential as a once-daily oral therapy.

Amid these developments, Fulcrum Therapeutics, Inc. (NASDAQ:FULC) priced a public offering on December 10, 2025, which is expected to raise $175 million in gross proceeds and provide additional balance sheet flexibility.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company focused on developing small molecules. Led by pociredir, these molecules aim to address genetically defined rare diseases such as sickle cell disease.